Stockscreener 앱 받기
0.0221
1.85%
0.000401
전일 마감가:
$0.0217
열려 있는:
$0.022
하루 거래량:
3,669
Relative Volume:
0.22
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-32.82%
1개월 성능:
-61.76%
6개월 성능:
-78.33%
1년 성능:
-35.94%
1일 변동 폭
$0.022
$0.0251
1주일 범위
$0.0217
$0.0354
52주 변동 폭
$0.0217
$34.93
Geovax Labs Inc Stock (GOVXW) Company Profile
명칭
Geovax Labs Inc
전화
678 384 7220
주소
1900 Lake Park Drive, Suite 380, Smyrna
GOVXW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GOVXW
Geovax Labs Inc
|
0.0222 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.01 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.22 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.86 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.48 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.64 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Geovax Labs Inc 주식(GOVXW)의 최신 뉴스
D. Boral Capital Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $9.00 - Defense World
GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Geode Capital Management LLC Has $223,000 Holdings in GeoVax Labs, Inc. (NASDAQ:GOVX) - Defense World
Geovax highlights progress on mpox vaccine and COVID-19 trial advancements - MSN
GeoVax Labs Earnings Call: Mixed Sentiment and Future Prospects - TipRanks
Geovax Labs (GOVX) Faces Price Target Reduction by Analyst | GOV - GuruFocus
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
GeoVax Labs Reports Q1 2025 Progress Amid Challenges - TipRanks
Earnings call transcript: GeoVax Q1 2025 reveals revenue from BARDA contract - Investing.com
GeoVax Labs Q1 2025 Earnings Call Transcript - MarketBeat
Geovax Labs is a buy, Roth says - Cantech Letter
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - ADVFN
GOVX’s 2023 Market Dance: Down -59.51% – Time to Invest? - investchronicle.com
Geovax Labs Inc (GOVX) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater - Yahoo Finance
GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress - Yahoo Finance
GeoVax to Host Q1 2025 Financial Results Conference Call, Spotlight COVID-19 Vaccine and Cancer Therapy Progress - citybuzz -
GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025 - The Globe and Mail
GeoVax Bolsters Technical Development with Seasoned Biologics Executive - citybuzz -
GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations - The Globe and Mail
Analysts Issue Forecasts for GeoVax Labs FY2029 Earnings - Defense World
HC Wainwright Estimates GeoVax Labs FY2025 Earnings - Defense World
Alliance Global Partners Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $8.50 - Defense World
HC Wainwright Reiterates Buy Rating for GeoVax Labs (NASDAQ:GOVX) - Defense World
Q2 EPS Estimates for GeoVax Labs Lowered by Noble Financial - Defense World
GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates - Yahoo Finance
GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital - Yahoo Finance
GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum - Yahoo Finance
Geovax Labs stock hits 52-week low at $0.78 amid market challenges By Investing.com - Investing.com South Africa
Top Midday Decliners - marketscreener.com
These Numbers Reveal How Powerful Geovax Labs Inc (NASDAQ: GOVX) Stock Is - stocksregister.com
GeoVax Labs (GOVX) Faces Setback with Price Target Reduced by Ro - GuruFocus
GeoVax Labs (GOVX) Faces Setback with Price Target Reduced by Roth Capital | GOVX Stock News - GuruFocus
GeoVax to Present at the Emerging Growth Conference on April 16, 2025 - Yahoo Finance
GeoVax (GOVX) Faces Setback with Termination of COVID-19 Vaccine Project | GOVX Stock News - GuruFocus
GeoVax's COVID-19 Vaccine Study Ended by Funding Agency; Shares Fall - MarketScreener
GeoVax Labs (GOVX) Faces Setback as BARDA-Funded Trial Ends | GO - GuruFocus
Geovax Labs stock hits 52-week low at $0.78 amid market challenges - Investing.com Canada
GeoVax to Present Clinical Data at Upcoming April Industry Events - Yahoo Finance
GeoVax Labs (GOVX): Price Target Lowered Amid BARDA Project Pause | GOVX Stock News - GuruFocus
GeoVax Labs contract with BARDA terminated By Investing.com - Investing.com South Africa
GeoVax Labs Got Written Notification From Advanced Technology International - MarketScreener
GeoVax tumbles as HHS ends mid-stage COVID vaccine trial - TradingView
GeoVax Labs contract with BARDA terminated - Investing.com
Geovax labs director John Spencer buys $9,800 in stock - Investing.com Australia
GeoVax Labs (NASDAQ:GOVX) Earns “Buy” Rating from D. Boral Capital - Defense World
Geovax labs director John Spencer buys $9,800 in stock By Investing.com - Investing.com Canada
Geovax labs VP John Sharkey acquires $5,940 in common stock By Investing.com - Investing.com Canada
GeoVax Labs (GOVX) Gains Favor with BARDA Contract Amid FDA Vacc - GuruFocus
Geovax labs VP John Sharkey acquires $5,940 in common stock - Investing.com Australia
GeoVax Labs, Inc. (NASDAQ:GOVX) Given Average Recommendation of “Buy” by Analysts - Defense World
Geovax Labs Inc (GOVXW) 재무 분석
Geovax Labs Inc (GOVXW)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):